J&J Strikes Deal with Biotech Startup for Alzheimer’s Treatment

By MedCity News

Mar 11, 2014

Johnson and Johnson’s Innovation Center will fund early R&D efforts for one of drug startup Alector’s targets, with the option to negotiate a commercial agreement if the startup can show proof of concept.

Alector is based at the Janssen Labs @QB3 innovation lab in San Francisco. The specifics about the monoclonal antibody being developed have not been disclosed, but  the early stage exploratory program has potential to enhance J&J's Alzheimer’s pipeline.

Read more at Med City News

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments